180
Participants
Start Date
February 1, 2020
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2025
Blinatumomab
"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
RECRUITING
Dmitry Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow
RECRUITING
National Medical Research Center of Oncology named after N.N. Blokhin, Moscow
RECRUITING
Russian Children's Clinic Hospital; Pirogov Russian National Research Medical University, Moscow
RECRUITING
Almazov National Medical Research Centre, Saint Petersburg
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
OTHER